These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 28444219

  • 1. DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors.
    Brown AL, Foster KL, Lupo PJ, Peckham-Gregory EC, Murray JC, Okcu MF, Lau CC, Rednam SP, Chintagumpala M, Scheurer ME.
    Neuro Oncol; 2017 Oct 01; 19(10):1372-1379. PubMed ID: 28444219
    [Abstract] [Full Text] [Related]

  • 2. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
    Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG.
    Pediatr Blood Cancer; 2014 Apr 01; 61(4):601-5. PubMed ID: 24504791
    [Abstract] [Full Text] [Related]

  • 3. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
    Moke DJ, Luo C, Millstein J, Knight KR, Rassekh SR, Brooks B, Ross CJD, Wright M, Mena V, Rushing T, Esbenshade AJ, Carleton BC, Orgel E.
    Lancet Child Adolesc Health; 2021 Apr 01; 5(4):274-283. PubMed ID: 33581749
    [Abstract] [Full Text] [Related]

  • 4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2014 Jul 01; (7):CD009219. PubMed ID: 24984156
    [Abstract] [Full Text] [Related]

  • 5. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
    Brown AL, Lupo PJ, Okcu MF, Lau CC, Rednam S, Scheurer ME.
    Cancer Med; 2015 Nov 01; 4(11):1679-86. PubMed ID: 26400460
    [Abstract] [Full Text] [Related]

  • 6. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review.
    Vieira WA, Weltman E, Chen MJ, da Silva NS, Cappellano AM, Pereira LD, Gonçalves MI, Ferrigno R, Hanriot RM, Nadalin W, Odone Filho V, Petrilli AS.
    Radiat Oncol; 2014 Jul 21; 9():158. PubMed ID: 25041714
    [Abstract] [Full Text] [Related]

  • 7. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD009219. PubMed ID: 22592737
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.
    Cohen-Cutler S, Wong K, Mena V, Sianto K, Wright MA, Olch A, Orgel E.
    Int J Radiat Oncol Biol Phys; 2021 Aug 01; 110(5):1488-1495. PubMed ID: 33677052
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity.
    Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, Carpenter LS, Mai WY, Chintagumpala MM, South M, Grant WH, Butler EB, Woo SY.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):599-605. PubMed ID: 11849779
    [Abstract] [Full Text] [Related]

  • 15. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC.
    Lancet Oncol; 2018 Dec 01; 19(12):1602-1616. PubMed ID: 30392813
    [Abstract] [Full Text] [Related]

  • 16. The Incidence and Risk Factors of Cisplatin and Carboplatin Ototoxicity in Pediatric Oncology Patients at Tertiary Oncology Center.
    Attar M, Alqarni MS, Alsinnari YM, Bukhari ZM, Alshegifi H, Alzhrani A, Alshaikh K, Alsubaie H, Muqat M, Alhakami H, Algarni M.
    Indian J Surg Oncol; 2022 Dec 01; 13(4):925-930. PubMed ID: 36687225
    [Abstract] [Full Text] [Related]

  • 17. Audiological Monitoring in Children Treated with Platinum Chemotherapy.
    Fetoni AR, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G, Paludetti G.
    Audiol Neurootol; 2016 Dec 01; 21(4):203-211. PubMed ID: 27286730
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.
    Clemens E, Brooks B, de Vries ACH, van Grotel M, van den Heuvel-Eibrink MM, Carleton B.
    PLoS One; 2019 Dec 01; 14(2):e0210646. PubMed ID: 30763334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.